Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...
Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
Denali and partner Sanofi SNY are ... programs in its pipeline. The FDA has selected its experimental candidate, DNL126, to support clinical trials advancing the rare disease therapeutics (START ...
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...
Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback